142 related articles for article (PubMed ID: 28213007)
1. Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells.
Sesumi Y; Suda K; Mizuuchi H; Kobayashi Y; Sato K; Chiba M; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
Lung Cancer; 2017 Feb; 104():85-90. PubMed ID: 28213007
[TBL] [Abstract][Full Text] [Related]
2. Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC.
Gohlke L; Alahdab A; Oberhofer A; Worf K; Holdenrieder S; Michaelis M; Cinatl J; Ritter CA
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834189
[TBL] [Abstract][Full Text] [Related]
3. Root Extract of
Park HJ; Park SH
Nutr Cancer; 2023; 75(10):1945-1957. PubMed ID: 37870977
[TBL] [Abstract][Full Text] [Related]
4. Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM.
Song KA; Niederst MJ; Lochmann TL; Hata AN; Kitai H; Ham J; Floros KV; Hicks MA; Hu H; Mulvey HE; Drier Y; Heisey DAR; Hughes MT; Patel NU; Lockerman EL; Garcia A; Gillepsie S; Archibald HL; Gomez-Caraballo M; Nulton TJ; Windle BE; Piotrowska Z; Sahingur SE; Taylor SM; Dozmorov M; Sequist LV; Bernstein B; Ebi H; Engelman JA; Faber AC
Clin Cancer Res; 2018 Jan; 24(1):197-208. PubMed ID: 29051323
[No Abstract] [Full Text] [Related]
5. [Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of
Non-small Cell Lung Cancer with MET Alterations].
Li S; Zhang X
Zhongguo Fei Ai Za Zhi; 2023 Sep; 26(9):684-691. PubMed ID: 37985154
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of drug resistance for EGFR-TKIs in lung cancer via multicellular lung-on-a-chip.
Tan J; Zhu L; Shi J; Zhang J; Kuang J; Guo Q; Zhu X; Chen Y; Zhou C; Gao X
Eur J Pharm Sci; 2024 May; 199():106805. PubMed ID: 38763450
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of newly discovered DNA aptamers targeting AXL in a lung cancer cell with acquired resistance to Erlotinib.
Hwang JA; Hur JY; Kim Y; Im JH; Jin SH; Ryu SH; Choi CM
Transl Cancer Res; 2021 Feb; 10(2):1025-1033. PubMed ID: 35116429
[TBL] [Abstract][Full Text] [Related]
8. Emergence of Resistance to MTI-101 Selects for a MET Genotype and Phenotype in EGFR Driven PC-9 and PTEN Deleted H446 Lung Cancer Cell Lines.
Jones C; Dziadowicz S; Suite S; Eby A; Chen WC; Hu G; Hazlehurst LA
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804837
[TBL] [Abstract][Full Text] [Related]
9. Mathematical Model of Intrinsic Drug Resistance in Lung Cancer.
Kozłowska E; Swierniak A
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958784
[TBL] [Abstract][Full Text] [Related]
10. Promising applications of nanotechnology in inhibiting chemo-resistance in solid tumors by targeting epithelial-mesenchymal transition (EMT).
Tangsiri M; Hheidari A; Liaghat M; Razlansari M; Ebrahimi N; Akbari A; Varnosfaderani SMN; Maleki-Sheikhabadi F; Norouzi A; Bakhtiyari M; Zalpoor H; Nabi-Afjadi M; Rahdar A
Biomed Pharmacother; 2024 Jan; 170():115973. PubMed ID: 38064969
[TBL] [Abstract][Full Text] [Related]
11. Exosomal lncCRLA is predictive for the evolvement and development of lung adenocarcinoma.
Lin S; He C; Song L; Sun L; Zhao R; Min W; Zhao Y
Cancer Lett; 2024 Feb; 582():216588. PubMed ID: 38097132
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib resistance in lung cancer: current progress and future perspectives.
Tang J; Salama R; Gadgeel SM; Sarkar FH; Ahmad A
Front Pharmacol; 2013; 4():15. PubMed ID: 23407898
[TBL] [Abstract][Full Text] [Related]
13. Tracking the EMT-like phenotype switching during targeted therapy in melanoma by analyzing extracellular vesicle phenotypes.
Zhou Q; Wang J; Zhang Z; Wuethrich A; Lobb RJ; Trau M
Biosens Bioelectron; 2024 Jan; 244():115819. PubMed ID: 37952322
[TBL] [Abstract][Full Text] [Related]
14. Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.
Zhang T; Qu R; Chan S; Lai M; Tong L; Feng F; Chen H; Song T; Song P; Bai G; Liu Y; Wang Y; Li Y; Su Y; Shen Y; Sun Y; Chen Y; Geng M; Ding K; Ding J; Xie H
Mol Cancer; 2023 Aug; 22(1):139. PubMed ID: 37598189
[No Abstract] [Full Text] [Related]
15. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.
Uchibori K; Inase N; Araki M; Kamada M; Sato S; Okuno Y; Fujita N; Katayama R
Nat Commun; 2017 Mar; 8():14768. PubMed ID: 28287083
[TBL] [Abstract][Full Text] [Related]
16. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
Yang JC; Ahn MJ; Kim DW; Ramalingam SS; Sequist LV; Su WC; Kim SW; Kim JH; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Lin CC; Mann H; Cantarini M; Ghiorghiu S; Jänne PA
J Clin Oncol; 2017 Apr; 35(12):1288-1296. PubMed ID: 28221867
[TBL] [Abstract][Full Text] [Related]
17. EGFR TKI combination with immunotherapy in non-small cell lung cancer.
Ahn MJ; Sun JM; Lee SH; Ahn JS; Park K
Expert Opin Drug Saf; 2017 Apr; 16(4):465-469. PubMed ID: 28271729
[TBL] [Abstract][Full Text] [Related]
18. T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non-Small Cell Lung Cancer.
Watanabe S; Yoshida T; Kawakami H; Takegawa N; Tanizaki J; Hayashi H; Takeda M; Yonesaka K; Tsurutani J; Nakagawa K
Mol Cancer Ther; 2017 Nov; 16(11):2563-2571. PubMed ID: 28839001
[TBL] [Abstract][Full Text] [Related]
19. The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated
Murakami Y; Sonoda K; Abe H; Watari K; Kusakabe D; Azuma K; Kawahara A; Akiba J; Oneyama C; Pachter JA; Sakai K; Nishio K; Kuwano M; Ono M
Oncotarget; 2017 Sep; 8(41):70736-70751. PubMed ID: 29050315
[TBL] [Abstract][Full Text] [Related]
20. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Murata Y; Kusumoto S; Ando K; Ishida H; Ohnishi T; Sasaki Y
Mol Cancer Res; 2017 Jul; 15(7):915-928. PubMed ID: 28289161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
